Process / pipelinecancer-specific quality of life, prostate cancer

UCLA Prostate Cancer Index: Functional Assessment of Prostate-Specific QoL

The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes.

Open in MethodMindSoonVideoSoon

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Sources

  1. Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012. DOI: 10.1097/00005650-199807000-00007
  2. Litwin, M. S., & Tan, H. J. (2017). The diagnosis and treatment of prostate cancer: a review. JAMA, 317(24), 2532–2542. DOI: 10.1001/jama.2017.7248

Related methods

Referenced by

ScholarGateUCLA Prostate Cancer Index (UCLA Prostate Cancer Index). Retrieved 2026-06-04 from https://scholargate.app/en/oncology/ucla-prostate-cancer-index